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PI3K isoforms are divided into three classes based on their structure and substrate specificity. Class IA PI3Ks are cytoplasmic heterodimers composed of a 110-kDa (p110␣, -␤, or -␦) catalytic subunit and an 85-kDa (p85, p55, or p50) adaptor protein. The catalytic subunits p110␣ and p110␤ are ubiquitously expressed in mammalian cells. Catalytic subunit p110␦ is expressed predominantly in lymphocytes and lymphoid tissues and therefore may play a role in PI3K-mediated signaling of immune responses (4) . Class IA isoforms are mainly activated by receptor and nonreceptor tyrosine kinases (RTKs), whereas class IB p110␥ is activated by G␤␥ subunits of G protein-coupled receptors (GPCRs) (31) . Class II isoforms are mainly associated with the phospholipid membranes and are present in the endoplasmic reticulum and Golgi apparatus (8) . Class III isoforms, structurally related to the yeast vesicular sorting protein Vps34p (33) , are mammalian homologs that use only membrane phosphatidylinositol as a substrate and generate phosphatidylinositol 3-monophosphate. Cellular levels of phosphatidylinositol 3-monophosphate are usually maintained at constant levels, suggesting that class III isoforms do not respond to extracellular stimuli. Despite PI3K playing an essential role in modulating mitogen-induced smooth muscle proliferation (15, 17) , the repertoire of PI3K isoforms expressed and their attendant functions have not been well studied in airway or vascular smooth muscle cells.
In asthma, chronic bronchitis, and atherosclerosis, smooth muscle mass is increased, in part, because of myocyte hyperplasia. Smooth muscle hyperplasia may be a normal response to injury and repair or, alternatively, myocyte growth may be a critical component of the pathobiology of these diseases. Despite consider-able effort, the precise signaling mechanisms that regulate smooth muscle cell proliferation in these diseases remain unknown. Evidence clearly suggests that smooth muscle mitogens may activate at least two types of receptors: GPCRs and those with intrinsic tyrosine kinases (RTKs). On ligand binding, these disparate receptors activate a variety of downstream signaling pathways that appear, in part, to converge to stimulate PI3K (32) . In a variety of cell types (7, 18, 31) , GPCR activation preferentially stimulates the class IB p110␥ isoform of PI3K, whereas RTK activation favors activation of either class IA or IB isoforms. Our studies, which used pharmacological inhibitors, suggest that Ras/mitogen-activated protein kinase and PI3K pathways are required for mitogen-induced airway smooth muscle (ASM) cell proliferation and that these pathways may act in parallel (1, (15) (16) (17) 29) . Epidermal growth factor (EGF) and thrombin, which are human ASM cell mitogens and are present in increased quantities in bronchoalveolar lavage fluid from asthmatic patients after allergen challenge, robustly stimulate PI3K via activation of the RTK and GPCR pathways, respectively (17) . In these cells, PI3K then stimulates p70
S6k
, the principal kinase that regulates translation of the mRNA transcripts necessary for G 1 cell cycle progression. Although such studies suggest that PI3K plays a central role in mediating mitogen-induced ASM cell proliferation, most investigators have relied on the specificity of pharmacological inhibitors to dissect such pathways; thus whether PI3K is sufficient and/or necessary to stimulate ASM cell growth remains unclear.
In this study, we characterized the specific isoforms expressed in human ASM cells. Using newly developed transient transfection techniques, we also investigated whether PI3K is necessary to thrombin-and EGFinduced DNA synthesis and whether PI3K activation alone is sufficient to induce DNA synthesis in these cells. Such studies are critically important in improving our understanding of the basic mechanisms that regulate smooth muscle cell proliferation and, hopefully, will foster the development of new therapeutic approaches to prevent or abrogate myocyte hyperplasia.
METHODS
Cell culture. Human tracheal tissue was obtained from lung transplant donors in accordance with procedures approved by the University of Pennsylvania Committee on Studies Involving Human Beings. A segment of trachea just proximal to the carina was removed under sterile conditions, and the trachealis muscle was isolated. With this technique, ϳ0.5 g of wet tissue was obtained, minced, centrifuged, and resuspended in 10 ml of buffer containing 0.2 mM CaCl 2, 640 U/ml of collagenase, 1 mg/ml of soybean trypsin inhibitor, and 10 U/ml of elastase. Enzymatic dissociation of the tissue was performed for 90 min in a shaking water bath at 37°C. The cell suspension was filtered through 105-m Nytex mesh, and the filtrate was washed with equal volumes of cold Ham's F-12 medium supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT). Aliquots of the cell suspension were plated at a density of 1.0 ϫ 10 4 cells/cm 2 . The cells were cultured in Ham's F-12 medium supplemented with 10% FBS, 100 U/ml of penicillin, and 0.1 mg/ml of streptomycin; this was replaced every 72 h.
Human ASM cells in subculture during the second through fifth cell passages were used because during these cell passages, the cells retain native contractile protein expression as demonstrated by immunocytochemical staining for smooth muscle actin and myosin (23) . These cells also retain functional signaling pathways that are important in mediating ASM contraction as determined by fura 2 measurements of agonist-induced changes in cytosolic calcium (21, 23) . All experiments were performed with a minimum of three different cell lines. Each human ASM cell line was established with tracheal tissue from a single human donor. Jurkat and U937 cells were purchased from the American Type Culture Collection (Manassas, VA).
Transfection of human ASM cells. Cultures of human ASM cells were transfected with the calcium phosphate transfection system (Life Technologies, Grand Island, NY) according to the manufacturer's protocol. The plasmid DNAs used in these studies were purified with the QIAGEN EndoFree Plasmid Maxi Kit (QIAGEN, Valencia, CA) and were endotoxin free. Cells were incubated with 10 g of either pEGFP-N1 (Stratagene, La Jolla, CA), pCG, pCG-p110*-Myc, pSR␣, or pSR␣-p85-HA plasmids (11) for 16 h. For experiments designed to examine whether transfection affects mitogen-induced DNA synthesis in ASM cells, the cells were washed with PBS and incubated for 48 h in Ham's F-12 medium supplemented with 10% FBS. Cultures were then trypsinized, resuspended in PBS, and sorted with the use of dual-wavelength flow cytometric analysis on a Coulter Epics-XL (Coulter, Hialeah, FL). Laser excitation for green fluorescent protein (GFP) was at 488 nm, with an emission wavelength of 525 nm. Sorted cells were plated at a density of 80,000 cells/well on two-well plastic chamber slides (Nunc, Naperville, IL) and incubated for 24 h in Ham's F-12 medium supplemented with 10% FBS. Monolayers were growth arrested by incubation in Ham's F-12 medium with 0.1% BSA for 48 h. Subsequently, the cells were treated with either 10 ng/ml of EGF (R&D Systems, Minneapolis, MN), 10% FBS, 1 U/ml of thrombin (Calbiochem, San Diego, CA), or diluent. After 16-18 h of mitogen stimulation, human ASM cells were labeled with 10 M 5-bromo-2Ј-deoxyuridine (BrdU) for 24 h. Detection of BrdU incorporation was performed as described in Microinjection and measurement of DNA synthesis.
For the cloning of stable transfectants of human ASM cells, the cells were transfected with the aforementioned calcium phosphate method with a pEGFP-N1 plasmid that encoded the neomycin resistance gene. After 48 h, the cells were trypsinized and replated on 100-mm plates at a 1:20 dilution and were cultured in 10% FBS-containing Ham's F-12 medium supplemented with 300 g/ml of Geneticin (G418; Life Technologies, Grand Island, NY). The colonies were then tested for expression of GFP with a Nikon microscope equipped with appropriate GFP filters. Clones containing 100% GFP-positive cells were then plated on 24-well plates at a density of 18,000 cells/well for [ 3 H]thymidine incorporation studies.
Microinjection and measurement of DNA synthesis. Nearconfluent human ASM cells grown on two-well plastic chamber slides (Nunc, Naperville, IL) were growth arrested. Microinjection pipettes (Femtotip I, Eppendorf, Hamburg, Germany) were filled with either Tris-EDTA buffer with 5 mg/ml of rabbit IgG, 0.375 mg/ml of pCG-p110* with 5 mg/ml of rabbit IgG, or 0.375 mg/ml of pCG-p110DN with 5 mg/ml of rabbit IgG. Rabbit IgG served as a marker for the microinjected cells. Microinjection was performed as described previously (1) . Briefly, ϳ2 h after microinjection, human ASM cells were treated with 10 ng/ml of EGF, 1 U/ml thrombin, 10% FBS, or diluent. Fifteen hours later, the thymidine analog BrdU (10 M) was added to all wells. Twenty-four hours after the addition of BrdU, the cell monolayers were fixed with 3.7% paraformaldehyde (Polysciences, Warrington, PA) and then permeabilized with 0.1% Triton X-100. After denaturation of the DNA with 4 N HCl (3 min at room temperature), the monolayers were incubated for 1 h at 37°C with 2 g/ml of murine anti-BrdU antibody (Becton Dickinson, San Jose, CA) and then with 10 g/ml of Texas Red-conjugated anti-mouse antibody for 1 h at 37°C (Jackson ImmunoResearch Laboratories, West Grove, PA) to detect BrdU-positive cells.
The slides were examined with a fluorescence microscope (Aristoplan, Leica, Wetzlar, Germany) with the appropriate fluorescence filters at ϫ200 magnification. Results are presented as mitotic index, defined as the percentage of BrdUpositive nuclei per number of cells microinjected. (24) on day 10. Near-confluent, growth-arrested cells were then used because cells can be synchronized in the G 0/G1 phase of the cell cycle, and at this baseline, they minimally incorporate [ 35 S]methionine and [
3 H]thymidine (23, 24) . After 24 h in serum-free medium, the cells were stimulated with either 10 ng/ml of EGF, 10% FBS, or 1 U/ml of thrombin. After 16-18 h of stimulation, human ASM cells were labeled with 3 Ci/ml of [methyl-
3 H]thymidine (40-60 Ci/mmol; Amersham Pharmacia, Arlington Heights, IL) for 24 h. The cells were then scraped and lysed, and the protein or DNA was precipitated with 10% trichloroacetic acid. The precipitant was aspirated onto glass filters, extensively washed, dried, and counted (23, 24) .
RT-PCR analysis. RT-PCR analysis was performed as described (5). Briefly, total RNA was extracted from growtharrested ASM cells with the acid-phenol method (5). cDNA was produced from this RNA by reverse transcription with oligo(dT) primers (Promega, Madison, WI) and Superscript II reverse transcriptase (Life Technologies, Grand Island, NY). Specific cDNAs for the PI3K isoforms were amplified with primer pairs (Table 1) by PCR for 30 cycles: denaturing at 94°C for 30 s, annealing at 56°C for 30 s, and extension at 72°C for 30 s. The primer pairs yielded the appropriate sizes of RT-PCR products as determined by electrophoresis in 1% agarose gels (5) . The RT-PCR products were subcloned into Bluescript SKϩ (Stratagene, La Jolla, CA), and their nucleotide sequences were confirmed by dideoxy sequencing with Sequenase (USB/Amersham).
Immunolocalization of hemagglutinin-tagged p85. ASM cells transiently transfected with pSR␣-p85-HA (11) or control pSR␣ cDNA were growth arrested for 48 h in Ham's F-12 medium supplemented with 0.1% BSA. The cells were then stimulated with 1 U/ml of thrombin for 5 or 15 min or treated with diluent alone. Cells were washed with ice-cold PBS, fixed with 2% paraformaldehyde, and blocked with 2% FBS in PBS. Immunostaining was performed with 0.5 g/ml of a primary anti-hemagglutinin (HA) tag mouse monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a 1:200 dilution of secondary Alexa 594 antibody (Molecular Probes, Eugene, OR). Immunofluorescence was viewed at ϫ630 magnification with a Zeiss Axiovert LSM150 confocal microscope.
Data analysis. Data points from individual assays represent the mean values of triplicate measurements. Significant differences among groups were assessed with ANOVA (Bonferroni-Dunn test) or by 2 analysis, with values of P Ͻ 0.05 sufficient to reject the null hypothesis for all analyses. All experiments were designed such that matched control conditions existed within each experiment to enable statistical comparison of paired samples. Each set of experiments was performed with a minimum of three different human ASM cell lines.
RESULTS

PI3K isoforms in human ASM cells.
In most cell types, a variety of PI3K isoforms are expressed. Activation of PI3K isoforms appears to modulate specific cellular functions. To date, the repertoire of PI3K isoforms expressed in human ASM remains unknown. With the use of specific primers (Table 1) and RT-PCR, the PI3K isoforms expressed in human ASM were characterized. As shown in Fig. 1 , analysis of the RT-PCR products from human ASM cells revealed expression of class IA p110␣ and p110␤, class II, and class III PI3K isoforms. Class IB p110␥ PI3K was not detected by RT-PCR. To confirm the specificity of the primers designed for class IB p110␥ PI3K, RT-PCR was performed with total RNA from Jurkat and U937 cells, which are known to express this isoform. In Jurkat and U937 cells, but not human ASM cells, p110␥ was present. Protein expression of class IA PI3K was also examined by immunoprecipitation and immunoblotting with specific antibodies to the p85, p110␣, and p110␤ isoforms as shown in Fig. 2 . Immunoprecipitation and immunoblotting with an anti-p110␥ antibody revealed no p110␥ isoforms in human ASM cell lysates (data not shown). These data suggest that human ASM cells express class IA, II, and III PI3K but not the class IB p110␥ isoform. The absence of class IB p110␥ is interesting because this isoform has been implicated in GPCR activation, which mediates agonist-induced cytosolic calcium mobilization in a variety of cells. 
Primers were used to identify phosphatidylinositol 3-kinase (PI3K) isoforms in airway smooth muscle cells.
The HA-p85 regulatory subunit of class IA PI3K translocates to the cell membrane after thrombin stimulation of human ASM cells. Evidence suggests that GPCRs may activate class IA or class IB PI3K and that this activation appears to be cell and tissue specific. In most cell types, the class IB p110␥ isoform appeared to be important in mediating GPCR effects. Because our laboratory (17) previously described the fact that thrombin stimulates human ASM cell DNA synthesis by activation of a pertussis toxin-sensitive GPCR and because human ASM cells do not express class IB p110␥ but activate PI3K, we were interested in characterizing the PI3K isoform that mediates the effects of thrombin in these cells. To determine whether class IA PI3K modulates thrombin-induced signaling in human ASM cells, monolayers were transiently transfected with the pSR␣-HA-p85 encoding HA-tagged p85 regulatory subunit of class IA PI3K. Transfected cells were plated on chamber slides, growth arrested for 24 h, and then stimulated with thrombin for 5 and 15 min or treated with diluent alone. Thrombin (1 U/ml) was used because in a previous study (17) , this concentration was optimal for activation of PI3K and DNA synthesis in human ASM cells. The translocation of the HA-tagged p85 was characterized by immunofluorescence microscopy. In control cells, HA-p85 was diffusely present throughout the cytoplasm as shown in Fig. 3 . After 5 min of thrombin stimulation, HA-p85 was no longer diffusely distributed in the cytosol but clustered near the cell membrane. Relocation of HAp85 was observed 5 and 15 min after stimulation with thrombin. These data suggest that thrombin activates a receptor that induces translocation from the cytosol to the plasmalemma of the transiently expressed HAp85 regulatory subunit of class IA PI3K. 2 . Class IA catalytic subunits of PI3K p110␣ and p110␤ form heterodimers with p85 regulatory subunits. HASM cells were immunoprecipitated with antibodies specific to either the p85 regulatory subunit or the p110␣ or -␤ catalytic subunits. Each immunoprecipitate (IP) was split into 3 samples, subjected to denatured SDS-PAGE, and immunoblotted (IB) with either anti-p85, anti-p110␣, or anti-p110␤ antibodies. These are representative immunoblots from 3 separate experiments with the same results.
Transfected human ASM cells retain proliferative responses to mitogens. In a variety of cell types, PI3K appears to be necessary for the mediation of cell growth and proliferation. In human ASM cells, it has been shown (6, 12, 17) that both RTK-and GPCR-dependent human ASM cell proliferation require PI3K activation. To date, however, there are no studies to suggest that PI3K activation in smooth muscle is sufficient to induce cell proliferation. Such studies require the ability to transfect cells with high-efficiency plasmids that would constitutively activate PI3K and not alter the ability of the cells to undergo DNA synthesis. Despite a number of laboratories having successfully transiently transfected ASM cells (22, 25) , to date no laboratory has demonstrated that the transiently transfected cells retain mitogen-induced proliferative responses.
To overcome these experimental obstacles, we developed a technique to transiently transfect human ASM cells with a modified calcium phosphate technique that did not interfere with the proliferative capacity of the cells. Monolayers transfected with pEGFP-N1, which expresses a red shift variant of wild-type GFP, enabled us to sort transfected cells with flow cytometry. After 24 h, human ASM cells expressing GFP were sorted from untransfected cells. Flow cytometric analysis of cells transfected with pEGFP-N1 demonstrated a significant (up to 70%) percentage of cells expressing GFP compared with cells treated with carrier DNA as shown in Fig. 4 . After cell sorting, the population of human ASM cells expressing GFP was enriched to Ͼ99% as shown in Fig. 5 . To determine whether the transfected cells were capable of undergoing mitogeninduced DNA synthesis, cells expressing and not expressing GFP were plated on chamber slides, growth arrested, and then stimulated with 10% FBS, EGF, thrombin, or diluent alone. After 40 h, BrdU incorporation, a measure of DNA synthesis, was determined with an anti-BrdU immunocytochemical analysis. Mitotic indexes were calculated for each of the growth stimuli. As shown in Fig. 6 , mitogen-induced DNA synthesis in cells transfected with pEGFP-N1 was no different from that in mock-transfected cells stimulated by mitogens. These data demonstrate that human ASM cells transfected with pEGFP-N1 reporter plasmid retained the ability to undergo mitogen-induced DNA synthesis.
To further investigate whether human ASM cells are capable of stable transfection and whether stably transfected human ASM cells retain mitogenic responses, cells were transfected with a pEGFP-N1 reporter plasmid containing a Geneticin-resistant gene that enabled the selection of cells that were stably transfected. After transfection, Geneticin was added, and Ͼ99% of the viable cells expressed GFP. These confluent cells were then growth arrested and stimulated with 10% FBS, thrombin, or EGF. As shown in Fig. 7 , FBS, thrombin, and EGF stimulated PI3K is sufficient to induce DNA synthesis in human ASM cells. Because human ASM cells could be stably transfected and because transfected cells retained proliferative responses, experiments were performed to address whether PI3K is sufficient to induce mitogenesis. Monolayers were transfected with p110* cDNA expressing the Myc-tagged constitutively active form of class IA PI3K, which can activate signaling pathways independent from receptor stimulation (13, 14) . To characterize whether p110* was present in transfected cells, immunoprecipitation of cell lysates with Myctagged specific antibodies followed by immunoblotting was performed. As shown in Fig. 8A , human ASM cells transfected with pCG-p110*-Myc markedly expressed p110*-Myc compared with cells transfected with empty pCG plasmid. To address whether constitutively active PI3K is sufficient to induce DNA synthesis, monolayers were transfected with constitutively active p110* PI3K, and BrdU incorporation was then measured. As shown in Fig. 8B and Table 2 , expression of constitutively active p110* alone was sufficient to induce BrdU incorporation compared with cells transfected with empty plasmid. Mitotic index of pCG-p110*-transfected cells was 8.196% compared with 0.780% in control cells (P Ͻ 0.05 by 2 test). Interestingly, expression of p110* also significantly augmented EGF-stimulated DNA synthesis but had little effect on thrombin-or FBS-induced DNA synthesis. In parallel experiments, cells were transfected with a dominant negative PI3K, and mitogen-induced DNA synthesis was determined. Unfortunately, transient transfection of ASM cells with dominant negative p110DN PI3K caused monolayers to detach from the culture plates (data not shown). We speculated that during the prolonged exposure to the p110DN PI3K, cells may have experienced toxicity. To address these concerns, we performed single-cell microinjection techniques utilizing p110DN PI3K and investigated the effect of transfecting this plasmid on mitogen-induced DNA synthesis. This technique decreased the exposure of the cells to the dominant negative plasmid from 7 days to 40 h. As shown in Fig. 9 and Table 3 , cells microinjected with the p110DN PI3K had significantly decreased EGF-, thrombin-, and FBS-induced DNA synthesis compared with those cells microinjected with empty plasmid. Interestingly, the dominant negative p110DN PI3K did not completely abrogate mitogen-induced DNA synthesis. Importantly, cells injected with constitutively active p110* but not stimulated with mitogens had markedly enhanced BrdU incorporation compared with cells microinjected with control vector. Furthermore, EGF-and thrombin-induced DNA synthesis was enhanced in the presence of microinjected pCG-p110* compared with cells microinjected with vector alone. Interestingly, serum-induced DNA synthesis was unaffected in cells microinjected with the constitutively active PI3K. Collectively, these data show that constitutively active p110* is sufficient to induce DNA synthesis in human ASM cells and that EGF-but not thrombin-or serum-induced DNA synthesis can be augmented in cells transfected with constitutively active p110* PI3K.
DISCUSSION
In a variety of diseases, smooth muscle cell growth and proliferation represent pathogenetic mechanisms or responses to injury and repair that markedly alter myocyte function. In asthma, ASM hyperplasia characteristically defines airway remodeling, a complex lesion observed in the bronchi of patients with chronic severe asthma. Despite a considerable research effort, the precise mechanisms that regulate ASM cell proliferation remain unclear. New evidence, however, suggests that mitogens activate receptors whose downstream signaling events activate PI3K. In vitro studies with pharmacological inhibitors suggest that PI3K is essential for myocyte proliferation. PI3K, however, is a The mitotic index is the ratio of the percentage of 5-bromo-2Ј-deoxyuridine (BrdU)-positive cells to total number of cells counted. EGF, epidermal growth factor; FBS, fetal bovine serum.
family of kinases whose members modulate differential functions in the cell. To date, the repertoire of PI3K isoforms expressed in ASM and their function remain unclear. In this study, we demonstrated that human ASM cells express class IA, II, and III PI3K but not the class IB isoform. We showed that activation of a GPCR by thrombin induced translocation of class IA PI3K and that this isoform not only mediated thrombininduced DNA synthesis but also that of EGF-and serum-induced responses. We now show that constitutively active p110* class IA PI3K is sufficient to induce DNA synthesis in human ASM cells.
Current evidence suggests that PI3K activation modulates a variety of physiological functions that appear to be cell specific. With regard to cell proliferation, PI3K activation appears to be required for cell growth induced by some but not all mitogens (28) . Homozygous deletion of the p110␣ catalytic subunit of PI3K in transgenic mice induces early embryonic lethality that may be due to profound alterations in the proliferative capacities of a variety of cell types (3). In another study (3), fibroblasts isolated from p110␣ knockout mice failed to replicate in serum supplemented with growth factors (3). The p85␣-p55␣-p50␣-deficient mice also succumbed a few days after birth and had markedly impaired development and proliferation of B cells (9) . Interestingly, transgenic mice expressing constitutively active class IA PI3K, which is driven by the cardiac ␣-myosin heavy chain promoter, underwent marked cardiac hypertrophy, whereas mice expressing the dominant negative PI3K mutant controlled by the same promoter had markedly attenuated heart sizes (30) . Taken together, these studies suggest that class IA PI3K, not only in vitro but also in vivo, plays a critical role in modulating cell growth in mammalian development. In our study, we showed that human ASM cells express most PI3K isoforms but appear to be lacking the class IB p110␥ isoform.
In some cell types, activation of GPCR stimulates class IB PI3K-␥ activation (10, 19, 20, 26, 31, 34) . Despite these data, it is known that some cells do not express PI3K-␥ (2). The precise mechanisms by which GPCR activation stimulates PI3K remain unknown. Our laboratory (17) previously found that thrombin, a mitogen that activates a pertussis toxin-sensitive GPCR, stimulates PI3K activation and that the p85 regulatory subunit of class IA PI3K associates with tyrosine-phosphorylated proteins in response to thrombin. With wortmannin or LY-294002, we (17) showed that thrombin-induced ASM mitogenesis was completely abrogated. Collectively, these data suggest that in human ASM cells, GPCR activation stimulates class IA PI3K and that this isoform may modulate proliferative responses. In the current study, we demonstrated that after thrombin stimulation, HA-tagged p85 PI3K translocated from the cytosol to the cell membrane. These data suggest that a GPCR is capable of translocating class IA PI3K in human ASM cells.
To determine whether PI3K activation is necessary or sufficient to stimulate ASM cell DNA synthesis, we used a newly developed transfection technique that did not alter the proliferative capacity of the cells to respond to mitogens. The cells were transfected with a chimeric model of class IA PI3K in which the inter-SH2 region of the p85 regulatory subunit was covalently linked to its binding site at the p110 NH 2 -terminal region of the catalytic subunit. Klippel et al. (14) , using this form of constitutively active p110* in COS-7 cells, demonstrated that PI3K was sufficient for stimulation of Akt/Rac, c-Jun amino-terminal kinase, and p70
S6k . Previously, our laboratory also showed (17) that constitutively active p110* was sufficient for activation of p70 S6k in human ASM cells. We now show that tran- sient expression of constitutively active p110* is sufficient to induce DNA synthesis in ASM cells in the absence of mitogens. This finding is in agreement with the work of Klippel et al. (13) , who showed that activation of PI3K was sufficient to stimulate rat embryonic fibroblasts and COS-7 cells to enter the cell cycle. Interestingly, in human ASM cells, the level of p110*-induced DNA synthesis was markedly lower than that induced by EGF, thrombin, or serum, and thus although PI3K activation is sufficient to induce DNA synthesis in ASM cells, other signaling pathways that act in parallel or that are more effective inducers of PI3K may play a role in modulating mitogen-induced DNA synthesis in these cells. This notion is also supported by the experiments with the dominant negative PI3K construct. EGF-, thrombin-, or FBS-induced BrdU incorporation was decreased in cells microinjected with the dominant negative class IA p110 but was not completely inhibited.
Our study yields novel information on the regulation of human ASM cell mitogenesis. Several limitations regarding our study need to be addressed, however. A major limitation concerns the variability of transfection efficiency and the difficulty of interpretation of data obtained from a mixed population of transfected and untransfected cells. To overcome these difficulties, we performed fluorescence-activated cell sorting that allowed us to enrich the population of transfected cells to ϳ99% as shown in Fig. 5 . Although effective, these studies required a large number of cells and sophisticated cell-sorting techniques. In addition, the experimental approach in this study required cotransfection of cells with two plasmids, one containing GFP and the other the target gene. The cell sorting recognizes only GFP and assumes that the plasmid with the target gene is coinfected. Further studies need to be performed with the target gene cloned into the GFPcontaining plasmids and thus eliminate this concern. The physiological relevance of overexpression of target proteins can also be called into question. It was evident that prolonged overexpression of p110DN PI3K induced the cells to detach from the culture plates, which induced toxicity. Fortunately, our microinjection experiments decreased cell exposure time to p110DN and yielded useful data. A high level of p110* expression, as shown in Fig. 8A (17) , may also affect other cell functions apart from proliferation. We attempted to overcome these obstacles by using both transient transfection and microinjection techniques. As investigators, however, we recognize the limitations of such studies.
Together, our data show that in human ASM cells, most PI3K isoforms are expressed. More importantly, we showed that thrombin activates class IA PI3K and that this isoform is sufficient to induce DNA synthesis in human ASM cells without mitogen stimulation. Interestingly, inhibition of class IA PI3K, in part, inhibits mitogen-induced DNA synthesis. The lack of complete abrogation of mitogen-induced proliferative responses in human ASM cells suggests that other pathways parallel to PI3K activation likely modulate myocyte growth. Further studies are necessary to identify such pathways to define the mechanisms that regulate smooth muscle cell growth and that lead to the pathological findings of smooth muscle hyperplasia in such diseases as asthma, chronic bronchitis, and atherosclerosis.
